Current Treatment and Future Trends of Immunotherapy in Breast Cancer
Author:
Affiliation:
1. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and The University of Toronto, Toronto, Ontario, Canada
2. University of New South Wales, Kensington, New South Wales, Australia
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Reference89 articles.
1. Gradishar W.J.; NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Breast cancer version 4. Available from: 2021
2. Thorsson V.; Gibbs D.L.; Brown S.D.; Wolf D.; Bortone D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; Ziv, E.; Culhane, A.C.; Paull, E.O.; Sivakumar, I.K.A.; Gentles, A.J.; Malhotra, R.; Farshidfar, F.; Colaprico, A.; Parker, J.S.; Mose, L.E.; Vo, N.S.; Liu, J.; Liu, Y.; Rader, J.; Dhankani, V.; Reynolds, S.M.; Bowlby, R.; Califano, A.; Cherniack, A.D.; Anastassiou, D.; Bedognetti, D.; Mokrab, Y.; Newman, A.M.; Rao, A.; Chen, K.; Krasnitz, A.; Hu, H.; Malta, T.M.; Noushmehr, H.; Pedamallu, C.S.; Bullman, S.; Ojesina, A.I.; Lamb, A.; Zhou, W.; Shen, H.; Choueiri, T.K.; Weinstein, J.N.; Guinney, J.; Saltz, J.; Holt, R.A.; Rabkin, C.S.; Lazar, A.J.; Serody, J.S.; Demicco, E.G.; Disis, M.L.; Vincent, B.G.; Shmulevich, I. The immune landscape of cancer. Immunity 2019,51(2),411-412
3. Azizi E.; Carr A.J.; Plitas G.; Cornish A.E.; Konopacki C.; Prabhakaran S.; Nainys J.; Wu K.; Kiseliovas V.; Setty M.; Choi K.; Fromme R.M.; Dao P.; McKenney P.T.; Wasti R.C.; Kadaveru K.; Mazutis L.; Rudensky A.Y.; Pe’er D.; Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2018,174(5),1293-1308.e36
4. Loi S.; Sirtaine N.; Piette F.; Salgado R.; Viale G.; Van Eenoo F.; Rouas G.; Francis P.; Crown J.P.; Hitre E.; de Azambuja E.; Quinaux E.; Di Leo A.; Michiels S.; Piccart M.J.; Sotiriou C.; Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013,31(7),860-867
5. Dieci M.V.; Criscitiello C.; Goubar A.; Viale G.; Conte P.; Guarneri V.; Ficarra G.; Mathieu M.C.; Delaloge S.; Curigliano G.; Andre F.; Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 2015,26(7),1518
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment;Discover Nano;2024-09-07
2. Application of hydrogels in cancer immunotherapy: a bibliometric analysis;Frontiers in Immunology;2024-08-13
3. Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germlineAPOBEC3Bdeletion: results of the phase II AUROR study;2024-08-07
4. Synthesis, pharmacological evaluation, and in silico study of new 3-furan-1-thiophene-based chalcones as antibacterial and anticancer agents;Heliyon;2024-06
5. Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer;Journal of Immunotherapy;2024-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3